Biomedical Engineering Reference
In-Depth Information
Therapeutic Areas
Phase I
Phase II Phase III
Filed
Approved
9
9
5
2
3
Biopharmaceuticals
Cardiovascular
& Metabolic
2
10
1
0
1
3
2
1
0
0
Infectious Diseases
1
7
1
2
0
Neurosciences
6
5
11
1
4
Oncology
1
1
0
0
0
Ophthalmology
Respiratory &
Immuno-inflamm
6
13
6
0
0
0
3
1
2
0
Paediatric Vaccines
2
2
2
2
0
Other Vaccines
Antigen Specific
Cancer Immuno
3
1
2
0
0
0
0
3
0
0
Rare Diseases
Dermatology
(Stiefel)
0
0
1
1
3
HIV (ViiV
Healthcare)
1
3
2
0
0
Overall
34
56
36
10
11
Fig. 3.2
Product development portfolio of GlaxoSmithKline (
2011b
)
Development (GlaxoSmithKline
2011a
). GSK hoped to improve accountability and
flexibility by keeping each unit small and focused (outsourcing-pharma.com
2003
).
A few years later in 2007, GSK launched Centers of Excellence for External Drug
Discovery (CEEDDs) to marry external innovation partners and their ideas with
GSK's areas of expertise. More recently, GSK has further reorganized its innovation
centers into Therapy Area Units (TAUs) consisting of even smaller Drug Performance
Units or DPUs (BiotechLive.com
2011
). Each unit is led by a CEO with the
Search WWH ::
Custom Search